Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 14, 2026 10:35 ET | Source: Research and Markets

Trends and Strategies Shaping the $4+ Billion Induced Pluripotent Stem Cell (iPSC) Market, 2026-2030: Major Collaborations and Advances in iPSC Technology Unveiled

Dublin, April 14, 2026 (GLOBE NEWSWIRE) -- The "Induced Pluripotent Stem Cell (iPSC) Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report delivers essential...
April 07, 2026 07:09 ET | Source: Pluristyx, Inc.

Pluristyx Extends Patent Portfolio in Universal Cell Therapy with New U.S. Patent for iACT Stealth™ Technology

Pluristyx announces a new U.S. patent for iACT Stealth™ technology, enabling "cloaking" of cells to treat autoimmune diseases without immune suppression.
March 17, 2026 07:37 ET | Source: Pluristyx, Inc.

Organoid COMMONS Announces Formation of Governing Board, Appointment of Alliance Director, and Announces Open Call for New COMMONS Members

Organoid COMMONS appoints its Governing Board and Alliance Director. Member applications are open through April 30, 2026.
February 05, 2026 07:07 ET | Source: Pluristyx, Inc.

Pluristyx and Solesis Launch First-of-its-Kind PluriForm™-GFP-3D Transfection Kit, Solving Critical Bottlenecks in Suspension Culture Transfection

Pluristyx and Solesis launch ready-to-use kit combining high-quality pluripotent cells and mRNA technology with proprietary transfection technology
January 21, 2026 02:46 ET | Source: Hopstem Biotechnology Inc.

FDA Granted Hopstem’s hNPC01 for Chronic Ischemic Stroke Approval to Enter Phase 2/3 Adaptive Pivotal Clinical Trial with Bridging Study

FDA Granted Hopstem’s hNPC01 for Chronic Ischemic Stroke Approval to Enter Phase 2/3 Adaptive Pivotal Clinical Trial with Bridging Study
January 08, 2026 08:00 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes

PHILADELPHIA, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies...
December 02, 2025 08:27 ET | Source: Pluristyx, Inc.

CORRECTION: Pluristyx Launches Organoid COMMONS, Uniting Industry Leaders to Revolutionize Drug Discovery

Pluristyx launches Organoid COMMONS, uniting 10 industry leaders to set global standards for human-relevant organoids and advance non-animal drug testing.
December 02, 2025 07:07 ET | Source: Pluristyx, Inc.

Pluristyx Launches Organoid COMMONS, Uniting Industry Leaders to Revolutionize Drug Discovery

Pluristyx launches Organoid COMMONS, uniting 10 industry leaders to set global standards for human-relevant organoids and advance non-animal drug testing.
November 17, 2025 08:55 ET | Source: Research and Markets

$Induced Pluripotent Stem Cell (iPSC) Global Market Opportunities And Strategies To 2034: Top 10 Players Hold 30.52% of 2023 Market, Led by FUJIFILM at 9.24% Share

Dublin, Nov. 17, 2025 (GLOBE NEWSWIRE) -- The "Induced Pluripotent Stem Cell (iPSC) Global Market Opportunities And Strategies To 2034" report has been added to ResearchAndMarkets.com's offering. ...
November 17, 2025 07:07 ET | Source: Pluristyx, Inc.

Pluristyx Collaborates with Breakthrough T1D to Make “Immune-Cloaked” and Safety Switch-Enabled Allogeneic Cell Line for Type 1 Diabetes Therapies

Pluristyx and Breakthrough T1D partner to engineer an immune-cloaked, safety-enabled iPSC line to advance universal islet therapies for type 1 diabetes.